Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 2
2014 2
2015 3
2016 1
2017 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
ALS/SURV: a modification of the CAFS statistic.
Goutman SA, Brown MB, Cudkowicz M, Atassi N, Feldman EL. Goutman SA, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):576-583. doi: 10.1080/21678421.2019.1643375. Epub 2019 Jul 23. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31334681 Free PMC article.
Patient-reported problematic symptoms in an ALS treatment trial.
Raheja D, Stephens HE, Lehman E, Walsh S, Yang C, Simmons Z. Raheja D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):198-205. doi: 10.3109/21678421.2015.1131831. Epub 2016 Jan 29. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26824413 Free PMC article. Clinical Trial.
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM; Ceftriaxone Study Investigators. Cudkowicz ME, et al. Lancet Neurol. 2014 Nov;13(11):1083-1091. doi: 10.1016/S1474-4422(14)70222-4. Epub 2014 Oct 5. Lancet Neurol. 2014. PMID: 25297012 Free PMC article. Clinical Trial.
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.
Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ. Zhao Y, et al. J Clin Pharmacol. 2014 Oct;54(10):1180-7. doi: 10.1002/jcph.317. Epub 2014 May 16. J Clin Pharmacol. 2014. PMID: 24771634 Free PMC article. Clinical Trial.
Analysis of start-up, retention, and adherence in ALS clinical trials.
Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin EA, Cudkowicz ME. Atassi N, et al. Neurology. 2013 Oct 8;81(15):1350-5. doi: 10.1212/WNL.0b013e3182a823e0. Epub 2013 Sep 4. Neurology. 2013. PMID: 24005339 Free PMC article. Review.
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis.
Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME; Northeast ALS Consortium. Berry JD, et al. PLoS One. 2013 Apr 17;8(4):e61177. doi: 10.1371/journal.pone.0061177. Print 2013. PLoS One. 2013. PMID: 23613806 Free PMC article. Clinical Trial.
12 results